Type 2 Inflammation is the underlying cause of CRSwNP in 80% of Patients.
IL-4 and IL-13 have distinct and overlapping roles with a broad impact on CRSwNP symptoms.
![](/.imaging/webp/sanofi-templates/w1080-16-9/dam/campus-sanofi-bh/campus-sanofi-bh-new/science/Images/image---2023-09-21T204111.056.png/jcr:content/image%20-%202023-09-21T204111.056.png)
Related articles
MAT-BH-2400335/v1/May2024
IL-4 and IL-13 have distinct and overlapping roles with a broad impact on CRSwNP symptoms.
By clicking on this link, you will be leaving the Campus Sanofi website and going to another, entirely independent website.
Please note: Sanofi provides these links as a service to its website visitors and users; however, Sanofi takes no responsibility for the information on any website but its own.